UroGen (NASDAQ:URGN) is a clinical stage biopharmaceutical company involved in the development of new treatment options with a focus on uro-oncology.
In this article, I will try to explain my skepticism on the company's new drug candidates.
The company’s new approach is based on the RTGel drug delivery platform. According to UroGen's company presentation, RTGel technology's base feature is the changing properties of the substance depending on the temperature of the environment, which is quite interesting in terms of drug delivery.
Image source: Company's Corporate Presentation
The company believes that this form